Preclinical efficacy and safety of an anti-IL-1β vaccine for the treatment of type 2 diabetes

Neutralization of the inflammatory cytokine interleukin-1β (IL-1β) is a promising new strategy to prevent the β-cell destruction, which leads to type 2 diabetes. Here, we describe the preclinical development of a therapeutic vaccine against IL-1β consisting of a detoxified version of IL-1β chemicall...

Descripción completa

Detalles Bibliográficos
Autores principales: Spohn, Gunther, Schori, Christian, Keller, Iris, Sladko, Katja, Sina, Christina, Guler, Reto, Schwarz, Katrin, Johansen, Pål, Jennings, Gary T, Bachmann, Martin F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4362373/
https://www.ncbi.nlm.nih.gov/pubmed/26015986
http://dx.doi.org/10.1038/mtm.2014.48

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4362373/
https://www.ncbi.nlm.nih.gov/pubmed/26015986
http://dx.doi.org/10.1038/mtm.2014.48

Ejemplares similares